Advair: profile and news
Pfizer's Norvasc reduces cardiovascular events Feb 8, 2006
...show that patients with high blood pressure and additional cardiovascular risk factors, who received Pfizer's calcium channel blocker Norvasc (marketed in ... - Express Pharma Pulse,
Biotechs take a stronghold on sales Mar 1, 2006
...makes three of the top 20 drugs in the United States, including cholesterol fighter Lipitor, Zoloft for depression and high- blood-pressure pill Norvasc. ... - Newark Star Ledger,
Pfizer steps up launches from global portfolio Mar 2, 2006
Caduet, a new generation cardiovascular drug, is a combination of atorvastatin calcium (Lipitor) and amlodipine besylate (Norvasc). ... - Economic Times,
UPDATE 2-Novartis files 2-in-1 blood pressure pill in EU Mar 3, 2006
...of Diovan, and amlodipine, which Pfizer Inc. (PFE.N: Quote, Profile, Research) markets as Norvasc. Novartis will not be able to ... - Reuters
Caduet (Amlodipine Besylate/Atorvastatin calcium), First Pill to ... Feb 14, 2006
...in Canada. Caduet combines the time-tested efficacy of Norvasc™ with the cardiovascular risk reduction of Lipitor®. Caduet may ... - DG News
Cause of high blood pressure a mystery Feb 5, 2006
These are his numbers even when he is on medication, such as Norvasc, which he is taking now. ... Norvasc is appropriate therapy but appears to be ineffective. ... - Northwest Herald,
HOME PAGE FOR THE WORLD'S BUSINESS LEADERS Mar 2, 2006
...first time. Next year it is the turn of Pfizer’s blood pressure drug, Norvasc, and allergy pill Zyrtec, also from Pfizer. The ... - Forbes
The Best-Selling Drugs In America Feb 27, 2006
What's more, Pfizer's Zoloft, for depression, and Norvasc, for high blood pressure, lose patent protection this year and next, respectively, potentially ... - Forbes
CADUET, First Pill to Treat High Blood Pressure and High ... Feb 14, 2006
CADUET combines the time-tested efficacy of NORVASC(TM) with the cardiovascular risk reduction of LIPITOR(R). CADUET may significantly prevent cardiovascular ... - Canada NewsWire (press release),
Pfizer Predicts Earnings Below Expectations and Flat Sales for '06 Feb 10, 2006
Analysts have been concerned about how such a large company can grow when it is losing patent protection on drugs like the blood pressure medication Norvasc. ... - New York Times,
Investors Seek Detailed Plan From Pfizer Feb 10, 2006
...but analysts still worry about how such a large company can grow when it is losing patent protection on drugs like blood pressure medication Norvasc, a $4.7 ... - The Kindred Times,
EARNINGS REPORTS Feb 11, 2006
...year as its top-selling cholesterol-lowering drug, Lipitor, faces increased competition from generic alternatives and blood-pressure drug Norvasc loses patent ... - Kansas City Star,
Pfizer forecasts higher profit from new drugs Feb 10, 2006
The company faces the loss of exclusivity for many of its key products -- Diflucan, Zithromax, Zoloft, Norvasc and Zyrtec -- over the next several years, but ... - Crain's New York Business,
Pfizer mulling OTC business sale Feb 8, 2006
10% to $3.9 billion in 2005, as overall revenues fell 2% to $51.3 billion on the back of patent losses on key product lines such as Norvasc (amlodipine), the ... - Pharma Times (subscription),
Flat now, Pfizer looking to acquisitions, new drugs Feb 12, 2006
...drugs are on the verge of losing sales to generics, with the anti-depressant Zoloft, the allergy pill Zyrtec and the blood pressure drug Norvasc expected to ... - Chicago Tribune,
WHO Pushes for Global Cooperation In War On Counterfeit Drugs Feb 16, 2006
The drug in question, Norvasc, is used to treat unstable angina and high blood pressure. An investigation prompted by a local woman ... - Newsinferno.com,
Pfizer is working against the clock Feb 19, 2006
2005 sales. Patent expires this year. Norvasc: A blood pressure treatment with $4.7 billion in sales. Patent expires in 2007. Zyrtec ... - DetNews.com,
Dr. Reddy's to Buy Betapharm for 480 Million Euros (Update5) Feb 16, 2006
...by an Indian company in Europe, will give it products including copies of GlaxoSmithKline Plc's Paxil antidepressant and Pfizer Inc.'s Norvasc heart medicine. ... - Bloomberg
Dr Reddy's to take over Betapharm Feb 16, 2006
...the biggest by an Indian company in Europe, will give it products such as copies of GlaxoSmithKline's Paxil antidepressant and Pfizer's Norvasc heart medicine. ... - The Standard,
Pfizer to unveil elixir for future Feb 9, 2006
He said revenue from the new drugs could offset declining sales of big Pfizer medicines that face the loss of patent protection, including Norvasc for high ... - Globe and Mail,
Pfizer sees '06 profit slightly under the weather Feb 10, 2006
In 2007, Pfizer stands to lose its patent on Norvasc, the blood pressure treatment with $4.7 billion in 2005 sales, and on Zyrtec, an allergy treatment with ... - CNN International
Cut Your Drug Costs Feb 10, 2006
...work for physicians. This program provides access to Pfizer's leading medicines, including Lipitor, Norvasc and Zoloft. To be eligible ... - Forbes
Mylan's Pipeline Not Compelling Enough Feb 3, 2006
...recent report. “We like the prospects for Norvasc, as we believe Mylan will somehow monetize this asset,� said the analyst. He ... - Forbes
Pfizer's Lipitor Keeps Top Spot Even as Growth Slows (Update1) Feb 15, 2006
...interview. Pfizer's Lipitor and Norvasc, the fourth-best selling medicine with $4.7 billion in revenue, may soon face generic challenges. ... - Bloomberg
Possible sale of Pfizer consumer unit wins support Feb 8, 2006
He said revenue from the new drugs could offset declining sales of big Pfizer medicines losing patent protection, including Norvasc for high blood pressure and ... - Reuters
Cheaper competition threatens top medicines Feb 15, 2006
Now Pfizer's Lipitor and the high-blood-pressure medicine Norvasc, the fourth-best selling medicine with $4.7 billion in revenue, may soon face generic ... - International Herald Tribune,
Mylan: Generic Drugs, Premium Price Feb 9, 2006
...example, while the company is cleared to begin selling generic Ditropan XL fairly soon, it's still battling with Pfizer(NYSE: PFE) over that firm's drug Norvasc ... - MSNBC
High Expectations Sink Drug Stocks Feb 4, 2006
...noted the key growth drivers for Mylan are its 11 "first-to-file" generic drug opportunities and highlighted generic versions of Pfizer's Norvasc and Johnson & ... - Forbes
Four questions for Pfizer Feb 7, 2006
And in 2007, Pfizer stands to lose its patent on Norvasc, the blood pressure treatment that totaled $4.7 billion in 2005 sales. ... - CNN/Money
Dubai, Dubai We're Selling You P&O. Goodbye ; THE WEEK THAT WAS Feb 12, 2006
Its shares closed down 2.5 per cent as analysts were left wondering how the company would ensure growth as Norvasc goes off patent and Lipitor, nears peak ... - International News Service,
Midday Business Report: Consider a mattress for Valentine gift Feb 10, 2006
...year as its top selling cholesterol-lowering drug Lipitor faces increased competition from generic alternatives and blood pressure drug Norvasc loses patent ... - Kansas City Star,
Huge drug haul from pharmacy Feb 7, 2006
Police say they haven't seen an illegal street trade in drugs like Lipitor, Norvasc or Losec, but "I'll put money down they're selling them for cash," Dunbar ... - Hamilton Spectator,
Intensifying research to fight diseases Feb 3, 2006
Celebrex 400) for acute pain and atorvastatin calcium/amlodipine besylate (Envacar), a combination of high blood pressure medicine Norvasc and cholesterol ... - INQ7.net,
With the Need to Focus on Rx Pipeline, Pfizer Mulls Divestiture of ... Feb 13, 2006
Faced with the impending patent expirations for some of its key prescription medications, including Zyrtec, Zoloft, and Norvasc, as well as challenges to ... - PharmaLive.com (press release),
